干扰素治疗慢性乙型病毒性肝炎疗效观察

The efficacy of interferon for treating chron ic hepatitis B

目的观察重组基因干扰素a-1b治疗慢性乙型病毒性肝炎(CHB)的临床疗效、影响因素及其安全性。方法选择门诊及住院的慢性乙型病毒性肝炎患者140例,其中干扰素治疗组84例;保肝治疗组56例。观察2组患者的肝功能、乙肝病毒标志物的变化和影响干扰素疗效的因素及干扰素a-1b的不良反应。结果①干扰素治疗组的ALT复常率和HBsAg阴转率均明显高于保肝治疗组,差异均无统计学意义(P>0.05);②干扰素治疗组中,女性治疗前高ALT水平、HBV-DNA≤106/ml的患者疗效更好;③干扰素a-1b的不良反应,主要为发热72例(占85.7%)、流感样症状50例(占59.5%)、白细胞减少40例(占47.6%)。不良反应一般不需作特殊处理,并能很快恢复正常,仅有2例白细胞减少者在加用升白细胞药物后恢复正常。结论干扰素a-1b是目前治疗慢性乙型病毒性肝炎较为有效且安全的可选择的药物。

Objective To observe the clinict,inpact factors and safety of recombinant human in terferon a-1b for treating chronic hepatitis B(CHB)cases Methods140 CHB cases selected from out and in patients were divivded into 2 groups :84 Cases in a-1b teratnent group,and 56 cases in liver protective group.Furthermore,a-1b treatment group was once again divided in to 3 subgroups according to sexes,AL T level and number of copies of HBV-DNA.The liver function,change of hepatitis B virusmarker,inpact factors of effectivenes and side effects were observed Results①in a-1b treatment group,the HBeAg negative rate,HBeAg senum inversion rate and HBV-DNA negative rate were significantly higher than that in liver protective group(P<0.01).②the ALT treatment group,better therapeutic effect revealed in females and those with higher ALT level and HBV-DVN≤106 copies/ml before treatment.③The side-effects of a-1b were fever(72 cases,85.7%),influenza-like symptoms(50 cases,59.5%)and leucopenia(40 cases,47.6%).Those with side-effects could recovery puickly without special treatment and only 2 cases with leukopnia were yecovery nomalafter heing treated with leukopenic drug.Conclusiona-1b interferon is one of the effective and safety medicines for treating CHB.